Monitoring For Rotavirus Serotypes In The Americas. Jon Gentsch

Size: px
Start display at page:

Download "Monitoring For Rotavirus Serotypes In The Americas. Jon Gentsch"

Transcription

1 Monitoring For Rotavirus Serotypes In The Americas Jon Gentsch Centers for Disease Control and Prevention, Atlanta, USA * The findings and conclusions in this presentation are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC). PAHO/WHO Collaborating Center for Rotavirus and Other Viral Agents of Gastroenteritis

2 Introduction Rationale for rotavirus strain surveillance Introduction to serotypes Surveillance in the Americas Conclusions and future directions

3 Rotavirus Strain Surveillance in Vaccine Era Vaccine Research Impact of vaccines on strain prevalence and evolution Will immune selection over time result in emergence of strains that escape protection? Vaccine stability Reversion to virulence Transmission, gastroenteritis in unvaccinated Reassortment with wild-type rotavirus Virus Evolution origin of new strains through reassortment Role of animal rotaviruses genetic variation in RV genes

4 Rotavirus Serotype Classification RNA Segment Protein VP1 VP2 VP3 VP4 NSP1 VP6 NSP2 NSP3 VP7 NSP4 NSP5 VP2 VP4 Neutralization antigen VP6 Subgroup antigen VP7 Neutralization antigen Subcore Provided by MK Estes P type G type

5 Methods: Processing Stool Samples for Strain Surveillance Rotavirus Detection (e.g., IDEIA (Oxoid [Ely]) Genotype positives using hemi-nested RT-PCR VP4 gene fragment (P) RT-PCR PCR P[11] P[6] P[8] P[9] P[4] P[10] P types VP7 gene fragment (G) PCR G9 G2 RT-PCR G4 G3 G types Identify genotypes by electrophoresis

6 Human Rotavirus Serotypes and Genotypes Four historically common strains globally (>30 yrs) P[8],2 or P[6],2 or P[4],2 or P[9],2 1.2% Unusual 7.5% Rare 0.5% P[8]G9 emerged since 1995 Emerged since 2000 P[8],G9 21.5% P[8],G4 6.6% P[8],G3 7.5% P[4],G2 11.8% P[8], 43.5% Data of K Banyai, PG types

7 Uncommon rotavirus genotypes: >20 G types, >30 P types and ~80 G-P combinations in humans Adapted from Kirkwood et al

8 Rotavirus Serotypes: Lessons learned from surveillance Only few globally common strains Periodic emerging strains Huge diversity Large temporal and geographic variation

9 Surveillance in the United States National Rotavirus Strain Surveillance System (NRSSS) New Vaccine Surveillance Network (NVSN) PAHO/WHO Collaborating Center for Rotavirus and Other Viral Agents of Gastroenteritis

10 National Rotavirus Strain Surveillance System (United States, ) Seattle San Francisco Omaha Kansas City Chicago Boston Hackensack Indianapolis Long Beach Fort Worth Atlanta Orlando

11 Number of Positive and Total Rotavirus Tests, United States, , 2008, 33 Continuously Reporting Labs 900 Total N Tests Total N Positive RotaTeq introduced

12 Longitudinal Variation of Rotavirus G Types in the United States ( ) RotaTeq introduced Number of Specimens NT G9 G4 G3 G G Hull, Teel et al, in prep Surveillance Year

13 Geographical Serotype Variation USA ( ) 2008) G9 39% other 3% 31% 6% G2 3% 4% G3 12% G2 15% G3 91% G3 96% Seattle WA, N=61 Omaha NE, N=40 Fort Worth TX, N=23 Hull, Teel et al, in prep

14 P and G Genotypes of Rotavirus Strains in United States (NRSSS) Other 7% P[4]G2 11% P[6]G9 1% Other 7% P[4]G2 13% P[8] 30% P[8]G9 3% P[8]G4 1% P[8]G3 2% P[8]G9 15% Hull, Teel et al, in prep TO P[8] 75% P[8]G3 35%

15 Genotyping by sequencing identified a major outbreak of genotype 2 in the United States (primers for 2 are not routinely present in multiplex RT-PCR) From Payne et al, PIDJ, 2009

16 Surveillance in Latin America and the Caribbean Set up starting 2004 to assess disease burden and strains Strains received from rotavirus sentinel hospital surveillance network analyzed at CDC Genotyping results from seven sites

17 Map of Countries Participating in the Rotavirus Surveillance Network in Latin America and the Caribbean St. Vincent & the Grenadines Venezuela Guyana Suriname Guatemala Honduras El Salvador Nicaragua Bolivia Chile Paraguay L Oliveira et al, JID 2009

18 Strains Circulating in Seven Latin American Countries ( ) other 7% untypeable 6% P[8] 32% P[8]G9 21% P[8]G8 10% P[8]G4 5% P[8]G3 1% P[4]G2 18% N=388 Adapted from L Oliveira et al, JID 2009

19 Regional Variation of Strains Circulating in the Latin American ( ) El Salvador Guatemala Guyana Honduras P[8]G9 20% P[8]G4 1% P[4]G2 11% untypeable other 5% 2% P[8] 61% P[8]G9 46% other 10% untypeable 4% P[8] 2% P[4]G2 38% P[8] 100% other 15% P[8]G9 9% untypeable 17% P[8]G4 2% P[8]G3 5% P[4]G2 52% Nicaragua St Vincent Suriname untypeable other 11% 4% P[8]G3 4% P[8] 6% P[6]2 7% other 5% untypeable 2% P[8] 2% P[8]G9 11% P[8]G4 70% P[8]G9 94% P[8]G8 84% Adapted from L Oliveira et al, JID 2009

20 Are Vaccination Programs Impacting Prevalence of Common Strains? Vaccination of populations with Rotarix Increased prevalence of P[4]G2 (Brazil, Australia) Vaccination with RotaTeq Increased prevalence of P[8]G3 (Australia, United States)

21 Temporal Variation in Predominant Strain,Central America P[8]G9 94% P[4]G2 81% P[8] 91% Vaccine El Salvador (Rotarix) Guatemala (none) P[8]G9 96% P[4]G2 72% P[8] 90% P[8]G9 40% P[4]G2 68% P[8 68% Honduras (none) Adapted from Patel et al., EID 2008; L Oliveira et al JID 2009

22 RotaTeq Vaccinated Population and increased P[8]G3 Rotavirus Genotypes in Nicaragua, P[4]G2 85% N=262, Patel et al, JAMA 2009

23 Conclusions and Future Directions No convincing evidence for immune selection, more likely natural variation Increasing prevalence P[4]G2, P[8]G3 in countries that have not adopted vaccines Supported by continued moderately high field efficacy of Rotarix vs P[4]G2 (e.g., Brazil, Australia [Snelling 2009, Nakagomi 2009], RotaTeq vs P[8]G3 [e.g., Boom et al 2008]) Long term effectiveness studies where serotype specific VE and overall disease trends can be assessed Needed to discriminate observed trends from natural strain fluctuations, emergence of new strains etc

24 CDC Umesh Parashar Margaret Cortese Manish Patel Dan Payne Jackie Tate Jazmin Vojdani Tara Kerin Mathew Esona Mike Bowen PAHO Lucia Helena de Oliveira M. Carolina Danovaro-Holliday Jon Kim Andrus Ana Maria Bispo de Fillipis Cuauhtemoc Ruiz Matus Epidemiological Surveillance of Ministries of Health from countries Members of the NVSN and NRSSS networks in the United States

Using surveillance data to monitor impact of rotavirus vaccine. Lúcia De Oliveira Regional Advisor on New Vaccines IM/PAHO

Using surveillance data to monitor impact of rotavirus vaccine. Lúcia De Oliveira Regional Advisor on New Vaccines IM/PAHO Using surveillance data to monitor impact of rotavirus vaccine Lúcia De Oliveira Regional Advisor on New Vaccines IM/PAHO Main Topics Epidemiological surveillance of rotavirus in American Region Impact

More information

Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas

Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas Eyal Leshem December 9, 2013 National Center for Immunization & Respiratory Diseases Division

More information

Vaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA

Vaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children

More information

Rotavirus vaccines: Issues not fully addressed in efficacy trials

Rotavirus vaccines: Issues not fully addressed in efficacy trials Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006

More information

Viral Agents of Paediatric Gastroenteritis

Viral Agents of Paediatric Gastroenteritis Viral Agents of Paediatric Gastroenteritis Dr Carl Kirkwood -------------------- Enteric Virus Research Group Murdoch Childrens Research Institute Royal Children s Hospital Victoria. WHO Collaborating

More information

developing countries in Latin America?

developing countries in Latin America? . How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th

More information

Regional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (March 15, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere,

Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere, 1 Introduction: Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere, 2003-2008 1 Enhanced measles elimination activities in the Region of the Americas during the

More information

Regional Update Pandemic (H1N1) 2009

Regional Update Pandemic (H1N1) 2009 Regional Update Pandemic (H1N1) 2009 (September 04, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 34 (EW 34), from 23 August to 29 August, 20 countries reported

More information

Pandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators

Pandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators Regional Update Pandemic (H1N1) 29 (August 28, 29-17 h GMT; 12 h EST) Update on the qualitative indicators For Epidemiological Week 33 (EW 33), from 16 August to 22 August, 22 countries reported updated

More information

Value of post-licensure data to assess public health value Example of rotavirus vaccines

Value of post-licensure data to assess public health value Example of rotavirus vaccines Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines

More information

Regional Update Pandemic (H1N1) 2009

Regional Update Pandemic (H1N1) 2009 Regional Update Pandemic (H1N1) 2009 (September 18, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 36 (EW 36), from 6 September to 12 September, 17 countries reported

More information

Regional Update Influenza (August 16, h GMT; 12 h EST)

Regional Update Influenza (August 16, h GMT; 12 h EST) Regional Update Influenza (August 16, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza

More information

Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI

Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI 2 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making

More information

Regional Update Pandemic (H1N1) 2009 (January 19, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (January 19, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (January 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

Regional Update Pandemic (H1N1) 2009 (December 1, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (December 1, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (December 1, 2009-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

Pandemic (H1N1) (August 14, h GMT; 12 h EST) Update on the Qualitative Indicators

Pandemic (H1N1) (August 14, h GMT; 12 h EST) Update on the Qualitative Indicators Regional Update Pandemic (H1N1) 2009 (August 14, 2009-17 h GMT; 12 h EST) Update on the Qualitative Indicators For epidemiological week 31 (EW 31, August 2 to August 8) 17 countries have reported updated

More information

Hepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages

Hepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages 2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,

More information

Regional Update Pandemic (H1N1) 2009 (July 19, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (July 19, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 9 (July 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza

More information

Regional Update Pandemic (H1N1) 2009 (July 6, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (July 6, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 29 (July 6, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza

More information

Regional Update Pandemic (H1N1) 2009 (May 24, h GMT; 12 h EST)

Regional Update Pandemic (H1N1) 2009 (May 24, h GMT; 12 h EST) Regional Update Pandemic (H1N1) 2009 (May 24, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National

More information

Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children,

Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, MAJOR ARTICLE Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012 2013 Daniel C. Payne, 1 Rangaraj Selvarangan, 2 Parvin H. Azimi, 3 Julie A. Boom,

More information

Influenza Vaccine Use In the Americas

Influenza Vaccine Use In the Americas Influenza Vaccine Use In the Americas Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-i Alba Maria Ropero-Alvarez Comprehensive Family Immunization Unit PAHO/FGL/IM Global Vaccine and

More information

Rubella and CRS Elimination in the Americas

Rubella and CRS Elimination in the Americas Rubella and CRS Elimination in the Americas Jon Kim Andrus, MD Deputy Director, PAHO Rome, Italy 8-10 February 2012 Presentation Opportunities for a rubella elimimation initiative The impact of the initiative

More information

Rotavirus Vaccines. Gagandeep Kang Christian Medical College Vellore

Rotavirus Vaccines. Gagandeep Kang Christian Medical College Vellore Rotavirus Vaccines Gagandeep Kang Christian Medical College Vellore Rotavirus disease burden Rotavirus vaccines and candidates Performance of vaccines in developed and developing countries Longitudinal

More information

Lessons from Rotavirus Vaccine Implementation in the U.S.

Lessons from Rotavirus Vaccine Implementation in the U.S. Lessons from Rotavirus Vaccine Implementation in the U.S. Jeff Duchin, MD Chief, Communicable Disease Epidemiology & Immunization Section Public Health - Seattle & King County Professor in Medicine, Division

More information

Molecular Characterization of Rotavirus Strains Circulating in Oman in 2005

Molecular Characterization of Rotavirus Strains Circulating in Oman in 2005 SUPPLEMENT ARTICLE Molecular Characterization of Rotavirus Strains Circulating in Oman in 2005 Said Al Baqlani, 1 Ina Peenze, 3 John Dewar, 3 Zainab Al Lawati, 1 Lindsey Pearson, 3 Varghese Rupa, 1 Charles

More information

Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine

Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases; Medical Research Council: Respiratory and

More information

Rotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation

Rotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation SUPPLEMENT ARTICLE Rotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation A. Duncan Steele, 1,2 Manish Patel,

More information

RESEARCH. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study

RESEARCH. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study 1 Ministerio de Salud, San Salvador, El Salvador 2 PanAmerican Health Organization, San Salvador 3 PanAmerican Health Organization, Washington, DC, USA 4 Viral Gastroenteritis Team, Epidemiology Branch,

More information

REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward

REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward SARInet annual meeting, Punta Cana, May 23 2017 Nathalie El Omeiri On behalf of REVELAC-i network, Alba

More information

Regional Update Pandemic (H1N1) 2009 (July 31, h GMT; 17 h EST) Update on the Qualitative Indicators Epidemiological Week 29 intensity

Regional Update Pandemic (H1N1) 2009 (July 31, h GMT; 17 h EST) Update on the Qualitative Indicators Epidemiological Week 29 intensity Regional Update Pandemic (H1N1) 2009 (July 31, 2009-22 h GMT; 17 h EST). Update onn thhe t Quual lli iit tati iivve InndiI iicatorss As of Epidemiological Week 29 (EW 29, July 19 to 25) all the 35 countries

More information

PAHO HIV REPORT. Progress of Implementation of the World Health Organization. Drug Resistance Strategy. in Latin America and the Caribbean:

PAHO HIV REPORT. Progress of Implementation of the World Health Organization. Drug Resistance Strategy. in Latin America and the Caribbean: OPS/FCH/HI/04-10.I PAHO HIV REPORT Progress of Implementation of the World Health Organization Drug Resistance Strategy in Latin America and the Caribbean: 2006 2009 June 2010 1 Progress of Implementation

More information

Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children

Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children Lilly Cheng Immergluck, Morehouse School of Medicine Trisha Chan Parker, Morehouse School of Medicine Shabnam Jain,

More information

Emergence of G12 and G9 rotavirus genotypes in the Central African Republic, January 2014 to February 2016

Emergence of G12 and G9 rotavirus genotypes in the Central African Republic, January 2014 to February 2016 https://doi.org/1.1186/s1314-17-3122-7 BMC Research Notes RESEARCH NOTE Emergence of G12 and G9 rotavirus genotypes in the Central African Republic, January 214 to February 216 Ulrich Aymard Ekomi Moure

More information

PAHO WORKSHOP ON CERVICAL CANCER PREVENTION STRATEGIES USING VIA SCREENING AND CRYOTHERAPY TREATMENT

PAHO WORKSHOP ON CERVICAL CANCER PREVENTION STRATEGIES USING VIA SCREENING AND CRYOTHERAPY TREATMENT PAHO WORKSHOP ON CERVICAL CANCER PREVENTION STRATEGIES USING VIA SCREENING AND CRYOTHERAPY TREATMENT As part of the activities for implementing the Regional Strategy and to promote the new approaches for

More information

US Rotavirus Vaccination Program

US Rotavirus Vaccination Program US Rotavirus Vaccination Program 1 Rotavirus Vaccines in US Feb 2006 Feb 2006 April 2008 June 2008 RotaTeq licensed by FDA RotaTeq recommended by ACIP Rotarix licensed by FDA ACIP to consider Rotarix 2

More information

Regional Update EW 32, 2012 Influenza (August 21, h GMT; 12 h EST)

Regional Update EW 32, 2012 Influenza (August 21, h GMT; 12 h EST) Regional Update EW 32, 2012 Influenza (August 21, 2012-17 h GMT; 12 h EST) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: www.paho.org/influenzareports

More information

Rotavirus. Rotavirus. Vaccine-Preventable Diseases WHO Vaccine-Preventable Diseases Surveillance Standards. Surveillance Standards

Rotavirus. Rotavirus. Vaccine-Preventable Diseases WHO Vaccine-Preventable Diseases Surveillance Standards. Surveillance Standards Last updated: September 5, 2018 Vaccine-Preventable Diseases Surveillance Standards 1 DISEASE AND VACCINE CHARACTERISTICS, a member of the reovirus family, causes watery diarrhoea, vomiting and severe

More information

Rotavirus vaccine impact on diarrhea associated child mortality, hospital admissions & clinical visits in Bolivia

Rotavirus vaccine impact on diarrhea associated child mortality, hospital admissions & clinical visits in Bolivia Rotavirus vaccine impact on diarrhea associated child mortality, hospital admissions & clinical visits in Bolivia Lucia Inchauste, Nataniel Mamani, Sonia Jimenez, Raul Montesano, Maritza Patzi, Rita Revollo,

More information

Case study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan

Case study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan 15 th ADVAC Case study Rota in Sudan Case study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan Background Rotavirus is one

More information

countries do not have information available for this indicator.

countries do not have information available for this indicator. Regional Update Pandemic (H1N1) 2009 (July 22, 2009-22 h GMT; 17 h EST) The data and information in this report will be updated on a weekly basis and available at: http://new.paho.org/hq/index.php?option=com_content&task=blogcategory&id=814&itemid=1206

More information

FIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS. Preventing Transmission

FIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS. Preventing Transmission FIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS Preventing Transmission Objectives Discuss the epidemiology of Zika virus Describe the Zika case investigation of the first confirmed case

More information

Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination

Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Manish Patel SAGE Geneva 12 April 2012 1 Overview! Update new inputs for benefit risk

More information

ROTAVIRUS VACCINES. Virology

ROTAVIRUS VACCINES. Virology ROTAVIRUS VACCINES Virology Rotavirus is a triple-layers viral particle belonging to the Reoviridae family. It contains 11 segments of double-stranded RNA, of which 6 are structural and 5 are non-structural

More information

Rotavirus: WHO Global Recommendations, Policy, and Surveillance

Rotavirus: WHO Global Recommendations, Policy, and Surveillance Rotavirus: WHO Global Recommendations, Policy, and Surveillance 9 th International Rotavirus Symposium 2 August 2010 Mary Agócs, MD, MSc Department of Immunization, Vaccines & Biologicals From 1999 2009:

More information

Alternative Rotavirus Vaccine Candidates: Why should we bother?

Alternative Rotavirus Vaccine Candidates: Why should we bother? Alternative Rotavirus Vaccine Candidates: Why should we bother? Duncan Steele Initiative for Vaccine Research, WHO 7 th International Rotavirus Symposium 12-13 June 2006, Lisboa, Portugal Rotavirus Vaccines

More information

Sustaining Immunization in Developing Countries: The Future We Make

Sustaining Immunization in Developing Countries: The Future We Make Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication

More information

20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009.

20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009. B. UPDATE ON THE PANDEMIC (H1N1) 2009 CD50/INF/6 (Eng.) - 7 - Annex B Background 20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus

More information

Rotavirus is the leading cause of severe diarrhea in

Rotavirus is the leading cause of severe diarrhea in GASTROENTEROLOGY 2009;137:1970 1975 Incidence of Rotavirus and All-Cause Diarrhea in Northeast Brazil Following the Introduction of a National Vaccination Program RICARDO G. GURGEL,*, ANNA K. BOHLAND,*

More information

*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a

*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a *This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a GDPH epidemiologist 404-657-2588, 8-5 pm M-F for current

More information

Regional Update EW 44 Influenza (November 15, h GMT; 12 h EST)

Regional Update EW 44 Influenza (November 15, h GMT; 12 h EST) Regional Update EW 44 Influenza (November 15, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: http://ais.paho.org/phip/viz/ed_flu.asp Influenza Regional Reports: www.paho.org/influenzareports

More information

Changes in Rotavirus Genotypes before and after Vaccine Introduction: a Multicenter, Prospective Observational Study in Three Areas of Japan

Changes in Rotavirus Genotypes before and after Vaccine Introduction: a Multicenter, Prospective Observational Study in Three Areas of Japan Jpn. J. Infect. Dis., 7, 448 452, 17 Original Article Changes in Rotavirus Genotypes before and after Vaccine Introduction: a Multicenter, Prospective Observational Study in Three Areas of Japan Takaaki

More information

Approaches to Assessing Intussusception Risk in Developing Countries

Approaches to Assessing Intussusception Risk in Developing Countries Approaches to Assessing Intussusception Risk in Developing Countries Jacqueline Tate Centers for Disease Control and Prevention Atlanta, GA, USA National Center for Immunization & Respiratory Diseases

More information

Rotavirus and Rotavirus Vaccines

Rotavirus and Rotavirus Vaccines Proceedings of the Seventh International Symposium June 12 13, 2006 Lisbon, Portugal Rotavirus and Rotavirus Vaccines Acknowledgements The Symposium Organizing Committee wishes to thank the following organizations

More information

Zika Operation: IMPACT IN THE AMERICAS. Americas Regional Office

Zika Operation: IMPACT IN THE AMERICAS. Americas Regional Office Zika Operation: IMPACT IN THE AMERICAS Americas Regional Office WHAT IS the Zika Operation in the Americas? The Zika Operation works to: Support National Societies in responding to the outbreak and implementing

More information

Taking vaccine effectiveness into public health decision making: The ProVac Example

Taking vaccine effectiveness into public health decision making: The ProVac Example http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz

More information

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Provisional Agenda Item 4.10

More information

Rotavirus Vaccine Impact and Effectiveness in Armenia and Moldova

Rotavirus Vaccine Impact and Effectiveness in Armenia and Moldova Rotavirus Vaccine Impact and Effectiveness in Armenia and Moldova Margaret M. Cortese, MD Centers for Disease Control and Prevention 12 th International Rotavirus Symposium, Melbourne, AUST Sept. 7, 2016

More information

Longitudinal Studies of Neutralizing Antibody Responses to Rotavirus in Stools and Sera of Children following Severe Rotavirus Gastroenteritis

Longitudinal Studies of Neutralizing Antibody Responses to Rotavirus in Stools and Sera of Children following Severe Rotavirus Gastroenteritis CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 1998, p. 897 901 Vol. 5, No. 6 1071-412X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Longitudinal Studies of

More information

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE

50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Agenda Item 4.17 27 September

More information

Regional Update EW 41 Influenza (October 25, h GMT; 12 h EST)

Regional Update EW 41 Influenza (October 25, h GMT; 12 h EST) Regional Update EW 41 Influenza (October 2, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza

More information

Ad-hoc Virtual TAG Meeting 2017

Ad-hoc Virtual TAG Meeting 2017 Ad-hoc Virtual TAG Meeting 2017 2 nd Ad-hoc Meeting of the Technical Advisory Group on Vaccine-preventable Diseases 10 March 2017 Washington, DC, USA TAG Members Dr. J. Peter Figueroa Professor Public

More information

Training in Infectious Diseases Modeling. A reflection on vaccination as a disease control measure

Training in Infectious Diseases Modeling. A reflection on vaccination as a disease control measure Training in Infectious Diseases Modeling A reflection on vaccination as a disease control measure -Example of Rotavirus disease- Participant s Guide Adapted by Nathalie Elomeiri; Camelia Savulescu; Fernando

More information

Special Topic. The ten leading causes of death in countries of the Americas

Special Topic. The ten leading causes of death in countries of the Americas The ten leading causes of death in countries of the Americas Table 1: Country specific information on the ten leading causes of death in broad age groups, by sex, for the latest two or three data years

More information

Inaccurate identification of rotavirus genotype G9 as genotype G3 strains due to primer mismatch

Inaccurate identification of rotavirus genotype G9 as genotype G3 strains due to primer mismatch Mitui et al. Virology Journal 2012, 9:144 SHORT REPORT Open Access Inaccurate identification of rotavirus genotype G9 as genotype G3 strains due to primer mismatch Marcelo Takahiro Mitui 1, TGA Nilmini

More information

9/11/2018. Rotavirus. Rotavirus. Rotavirus. First identified as a cause of diarrhea in 1973

9/11/2018. Rotavirus. Rotavirus. Rotavirus. First identified as a cause of diarrhea in 1973 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Rotavirus September 2018 Photographs and images included in this presentation are licensed solely for

More information

Regional Update EW 09 Influenza (March 15, h GMT; 12 h EST)

Regional Update EW 09 Influenza (March 15, h GMT; 12 h EST) Regional Update EW 09 Influenza (March 15, 2011-17 h GMT; 12 h EST) The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States

More information

Introduction to the ProVac Initiative

Introduction to the ProVac Initiative Introduction to the ProVac Initiative E-toolkit training module Nathalie El Omeiri, PAHO/WHO, Washington D.C. Family, Health Promotion and Life Course, Immunization unit, elomeirin@paho.org Contents of

More information

DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American Health Organization/ World Health Organization

DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American Health Organization/ World Health Organization DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American / World Outline Facts and Figures Suicide a major Public problem Suicide in the Americas Risk and Protective factors and related interventions

More information

Regional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014)

Regional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014) Regional Update EW 31, 2014 Influenza and other respiratory viruses (August 12, 2014) PAHO interactive influenza data: Uhttp://ais.paho.org/phip/viz/ed_flu.asp Influenza Regional Reports: www.paho.org/influenzareports

More information

Gastroenteritis Viruses Prof. Mary K. Estes

Gastroenteritis Viruses Prof. Mary K. Estes Gastroenteritis Viruses Mary K. Estes, Ph.D. Professor of Molecular Virology and Microbiology and Medicine-GI, BCM Director, Texas Medical Center DDC 1 Outline Gastrointestinal viruses Rotaviruses Noroviruses

More information

Update on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014

Update on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating

More information

Roger I. Glass, M.D., Ph.D. Director, Fogarty International Center Associate Director for International Research, NIH

Roger I. Glass, M.D., Ph.D. Director, Fogarty International Center Associate Director for International Research, NIH Rotavirus Vaccines: Prioritization for Introductions- National & International Case Studies Fondation Merieux Conference Center November 27, 2012 Roger I. Glass, M.D., Ph.D. Director, Fogarty International

More information

Everything you ever wanted to know about Zika Virus Disease

Everything you ever wanted to know about Zika Virus Disease Everything you ever wanted to know about Zika Virus Disease (in 14 slides) Jon Temte, MD/PhD University of Wisconsin School of Medicine and Public Health 28 January 2016 Zika Virus mosquito-borne flavivirus

More information

OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH

OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH Dr. Karen Lewis-Bell Advisor, Immunization Switch Monitoring Training Jamaica, December 9, 2015 Presentation Outline

More information

Figure 1: Suspected and confirmed Zika virus cases reported by countries and territories in the Americas, by epidemiological week (EW)

Figure 1: Suspected and confirmed Zika virus cases reported by countries and territories in the Americas, by epidemiological week (EW) Zika - Epidemiological Update 17 March 2016 Zika virus Incidence and trends Available data reported suggests a downward trend in reporting of Zika virus cases in the Region of the Americas (Figure 1).

More information

Overview of the ProVac Initiative

Overview of the ProVac Initiative Overview of the ProVac Initiative Updated Dec. 2017 Goal of the ProVac Initiative Strengthen evidence-based decision making on immunization to sustain and further the public health impact of immunization

More information

Lessons Learned and Best Practices of Achieving and Maintaining Measles and Rubella Elimination in the Americas

Lessons Learned and Best Practices of Achieving and Maintaining Measles and Rubella Elimination in the Americas Lessons Learned and Best Practices of Achieving and Maintaining Measles and Rubella Elimination in the Americas Jon Kim Andrus, MD Deputy Director, PAHO Rome, Italy 8-10 February, 2012 Presentation Outline

More information

Eradication of Wild Poliovirus from the Americas: Acute Flaccid Paralysis Surveillance,

Eradication of Wild Poliovirus from the Americas: Acute Flaccid Paralysis Surveillance, S37 Eradication of Wild Poliovirus from the Americas: Acute Flaccid Paralysis Surveillance, 1988-1995 Ciro A. de Quadros, Bradley S. Hersh, Jean-Marc Olive, Jon K. Andrus, Claudio M. da Silveira, and Peter

More information

Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations

Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,

More information

Edwin J. Asturias Associate Director

Edwin J. Asturias Associate Director Edwin J. Asturias Associate Director Center for Global Health Associate Professor of Pediatrics and Epidemiology Effectiveness Dengue Vaccine Washington DC, June 2014 UNIVERSITY OF COLORADO COLORADO STATE

More information

How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries?

How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries? How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries? Elmira Flem Department of Vaccines Norwegian Institute of Public Health Nordic Vaccine Meeting April

More information

Epidemiological Profile of Rotaviral Infection in India: Challenges for the 21st Century

Epidemiological Profile of Rotaviral Infection in India: Challenges for the 21st Century SUPPLEMENT ARTICLE Epidemiological Profile of Rotaviral Infection in India: Challenges for the 21st Century Gagandeep Kang, 1 Shobhana D. Kelkar, 2 Shoba D. Chitambar, 2 Pratima Ray, 3 and Trailokyanath

More information

VIRAL AGENTS CAUSING GASTROENTERITIS

VIRAL AGENTS CAUSING GASTROENTERITIS VIRAL AGENTS CAUSING GASTROENTERITIS VIRAL AGENTS CAUSING GASTROENTERITIS Pathogens discussed in our lectures 1. Rotavirus 2. Enteric adenoviruses 3. Caliciviruses 4. Astroviruses 5. Toroviruses Viruses

More information

Regional Update EW 43 Influenza (November 8, h GMT; 12 h EST)

Regional Update EW 43 Influenza (November 8, h GMT; 12 h EST) Regional Update EW 43 Influenza (November 8, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: www.paho.org/influenzareports

More information

Haemophilus influenzae type B and Hib Vaccine Chapter 9

Haemophilus influenzae type B and Hib Vaccine Chapter 9 Haemophilus influenzae type B and Hib Vaccine Chapter 9 Haemophilus influenzae Aerobic gram-negative bacteria Polysaccharide capsule Six different serotypes (a-f) of polysaccharide capsule 95% of invasive

More information

Regional Update EW 30 Influenza (August 9, h GMT; 12 h EST)

Regional Update EW 30 Influenza (August 9, h GMT; 12 h EST) Regional Update EW 30 Influenza (August 9, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: HUhttp://ais.paho.org/phip/viz/ed_flu.aspU Influenza Regional Reports: HUhttp://new.paho.org/hq/index.php?option=com_content&task=view&id=3352&Itemid=2469&to=2246U

More information

Decision-making by the Advisory Committee on Immunization Practices

Decision-making by the Advisory Committee on Immunization Practices Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012

More information

Considerations for Introduction of a Rotavirus Vaccine in Oman: Rotavirus Disease and Economic Burden

Considerations for Introduction of a Rotavirus Vaccine in Oman: Rotavirus Disease and Economic Burden SUPPLEMENT ARTICLE Considerations for Introduction of a Rotavirus Vaccine in Oman: Rotavirus Disease and Economic Burden S. A. Al Awaidy, 1 S. Bawikar, 1 S. Al Busaidy, 2 S. Baqiani, 2 I. Al Abedani, 1

More information

Rotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April

Rotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April Rotavirus serotype surveillance: Results and experiences in Tanzania Adolfine Hokororo KPA Vaccinology Symposium- 29 th April 2016 1 outline 1. Introduction-burden of RVGE 2. goals of RVGE sentinel surveillance

More information

ASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH

ASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH ASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH Michal Krzyzanowski WHO ECEH Bonn Office 1 Exposure - Response Population X Exposure IMPACT ESTIMATE FOR POPULATION X Population X health status WHO Air

More information

Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit

Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division

More information

Immunization Newsletter

Immunization Newsletter Immunization Newsletter Pan American Health Organization Volume XXXV Number 4 Immunize and Protect Your Family August 2013 XXI Meeting of PAHO s Technical Advisory Group (TAG) on Vaccine-preventable Diseases:

More information

General Description. Significance

General Description. Significance General Description The Zika virus is a member of the Flavivirus family, and is a small, enveloped virus (easy to kill with a hospital disinfectant). Zika virus is an emerging mosquito-borne virus that

More information

A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT. Introducing the Gates Medical Research Institute

A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT. Introducing the Gates Medical Research Institute A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research Institute MY JOURNEY A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research

More information

Enterovirus D68-US Outbreak 2014 Laboratory Perspective

Enterovirus D68-US Outbreak 2014 Laboratory Perspective Enterovirus D68-US Outbreak 2014 Laboratory Perspective Allan Nix Team Lead Picornavirus Laboratory Polio and Picornavirus Laboratory Branch PAHO / SARInet Webinar November 6, 2014 National Center for

More information

Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico

Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico original article Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico Vesta Richardson, M.D., Joselito Hernandez-Pichardo, M.D., Manjari Quintanar-Solares, M.D., Marcelino Esparza-Aguilar,

More information